Publications by authors named "Jonathan Steckbeck"

Claim this Profile
E
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.
David B Huang, Kimberly M Brothers, Jonathan B Mandell, Masashi Taguchi, Peter G Alexander, Jonathan D Steckbeck

PLoS One· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice.
Jan H Beumer, Jianxia Guo, Evan C Ray, Jonas Scemama, Robert A Parise, Jonathan D Steckbeck

Curr Rev Clin Exp Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.
David Huang, Despina Dobbins, Parviz Ghahramani, Ian Friedland, Jonathan Steckbeck

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components : The Knee Explant Analysis (KnEA) Study.
David Huang, Dana M Parker, Jonathan B Mandell, Kimberly M Brothers, Charles G Gish, Jonathan Steckbeck

Microbiol Spectr· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections.
David Huang, Nicholas Pachuda, John Michael Sauer, Dessie Dobbins, Jonathan Steckbeck

Antibiotics (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine.
Berthony Deslouches, Mary L Hasek, Jodi K Craigo, Jonathan D Steckbeck, Ronald C Montelaro

J Med Microbiol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei.
Suha Abdelbaqi, Berthony Deslouches, Jonathan Steckbeck, Ronald Montelaro, Douglas S Reed

J Med Microbiol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens.
Berthony Deslouches, Jonathan D Steckbeck, Jodi K Craigo, Yohei Doi, Jane L Burns

Antimicrob Agents Chemother· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41.
Anne-Sophie Kuhlmann, Jonathan D Steckbeck, Timothy J Sturgeon, Jodi K Craigo, Ronald C Montelaro

J Biol Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial peptides: new drugs for bad bugs?
Jonathan D Steckbeck, Berthony Deslouches, Ronald C Montelaro

Expert Opin Biol Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and functional comparisons of retroviral envelope protein C-terminal domains: still much to learn.
Jonathan D Steckbeck, Anne-Sophie Kuhlmann, Ronald C Montelaro

Viruses· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.
Jonathan D Steckbeck, Chengqun Sun, Timothy J Sturgeon, Ronald C Montelaro

PLoS One· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein.
Alexander L Boscia, Kiyotaka Akabori, Zachary Benamram, Jonathan A Michel, Michael S Jablin, Jonathan D Steckbeck

Biophys J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens.
Berthony Deslouches, Jonathan D Steckbeck, Jodi K Craigo, Yohei Doi, Timothy A Mietzner

Antimicrob Agents Chemother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.
Jonathan D Steckbeck, Anne-Sophie Kuhlmann, Ronald C Montelaro

J Gen Virol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.
Jonathan D Steckbeck, Jodi K Craigo, Christopher O Barnes, Ronald C Montelaro

J Biol Chem· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes.
Jonathan D Steckbeck, Chengqun Sun, Timothy J Sturgeon, Ronald C Montelaro

PLoS One· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.
Seth A Faith, Yingyun Wu, David Kuhrt, Jonathan D Steckbeck, Jodi K Craigo

Virology· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.
Rick A Bright, Donald M Carter, Corey J Crevar, Franklin R Toapanta, Jonathan D Steckbeck

PLoS One· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization.
Jonathan D Steckbeck, Kelly Stefano Cole

Immunol Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Soumi Gupta, Christian M Leutenegger, Gregg A Dean, Jonathan D Steckbeck, Kelly Stefano Cole

J Virol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains.
Jonathan D Steckbeck, Irina Orlov, Andrew Chow, Heather Grieser, Kenneth Miller

J Virol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
Jodi K Craigo, Feng Li, Jonathan D Steckbeck, Shannon Durkin, Laryssa Howe

J Virol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
Kelly Stefano Cole, Jonathan D Steckbeck, Jennifer L Rowles, Ronald C Desrosiers, Ronald C Montelaro

J Virol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
Feng Li, Jodi K Craigo, Laryssa Howe, Jonathan D Steckbeck, Sheila Cook

J Virol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis